Medication does not appear to reduce progression of atherosclerosis

Mar 17, 2009

Compared to placebo, the drug pactimibe did not effect certain measures of atherosclerosis for patients with familial hypercholesterolemia (high cholesterol levels), but these patients did have an increased incidence of cardiovascular events such as heart attack and stroke, according to a study in the March 18 issue of JAMA.

One proposed method to help prevent cardiovascular disease is to block the action of coenzyme A:cholesterol acyltransferase (ACAT), an enzyme involved in cholesterol accumulation. In theory, inhibition of ACAT-1 (an isoform [different form of the same protein] of ACAT) could slow the progression of (process in which plaque builds up in the inner lining of the ) and prevent the development of , according to background information in the article. Treatment with ACAT inhibitors, such as the drug pactimibe, have shown promising results for the prevention of atherosclerosis in various animal tests.

Marijn C. Meuwese, M.D., of the Academic Medical Center, Amsterdam, and colleagues assessed the efficacy and safety of pactimibe in reducing progression of atherosclerosis in 892 patients with a family history of high cholesterol, which is associated with a higher risk for atherosclerosis. The randomized, placebo-controlled study (Carotid Atherosclerosis Progression Trial Investigating Vascular ACAT Inhibition Treatment Effects [CAPTIVATE]) was conducted at 40 clinics in the United States, Canada, Europe, South Africa and Israel between February 2004 and December 2005. Participants received either 100 mg/d of pactimibe (n = 443) or matching (n = 438), in addition to standard lipid-lowering therapy. Atherosclerosis was assessed by ultrasound measurements of carotid intima-media thickness (CIMT; a measurement of the thickness of the inner wall of a major artery) at the beginning of the study and at 12, 18, and 24 months. Increasing thickness is considered a marker of increasing plaque in the artery. The treatment was discontinued on October 26, 2005, when the parallel ACTIVATE study failed to demonstrate efficacy of pactimibe vs. placebo.

After 6 months of treatment with pactimibe, the average percentage change from baseline of low-density-lipoprotein cholesterol (LDL-C) significantly increased by 7.3 percent compared with 1.4 percent in the placebo group. This increase in LDL-C was observed throughout the study and disappeared after discontinuation of the study drug.

The annual progression of maximum CIMT showed no difference between groups. However, the annual progression of the average CIMT showed a significant difference between groups as relative average CIMT increase was observed in patients receiving pactimibe (difference, −0.014 mm). Average CIMT progressed significantly in the pactimibe group within 1 year, whereas only minor progression of average CIMT was observed in the placebo group.

Serious adverse events were reported more frequently by patients in the pactimibe group than in the placebo group (10.0 percent vs. 7.7 percent). (6.3 percent vs. 3.4 percent) as well as the composite of cardiovascular death, , and stroke (2.3 percent vs. 0.2 percent) occurred more frequently in patients receiving pactimibe vs. placebo.

"… in patients with familial , pactimibe had no effect on atherosclerosis as assessed by changes in maximum CIMT compared with placebo but was associated with an increase in mean CIMT as well as increased incidence of major cardiovascular events," the authors write.

They add that the findings from this study and findings from other studies lessen "the promise and further development of this class of drugs for cardiovascular prevention."

More information: . 2009;301[11]:1131-1139

Source: JAMA and Archives Journals (news : web)

Explore further: Flu vaccine may hold key to preventing heart disease

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments : 0